Senate Pushes for FTC Progress in PBM Investigation
Senate Commerce Committee leaders, Maria Cantwell and Chuck Grassley, along with 12 lawmakers, are requesting an update from the Federal…
Browsing: Drug Pricing
“Plan E”: A Proposal for a Universal Benefit for Cell and Gene Therapies
Cell and gene therapies (CGTs) have provided new optimism for patients living with diseases previously considered untreatable. These groundbreaking treatments…
Aimed Alliance Release New Resources on PDABs
On January 22, 2024, Aimed Alliance published two new resources on prescription drug affordability boards (PDABs). These boards, established at…
FDA Authorizes Florida’s Drug Importation Program
On January 5, 2024, the U.S. Food and Drug Administration (FDA) approved Florida’s Agency for Health Care Administration drug importation…
CBO Responds to Calls from the House Budget Committee to Consider New Data on IRA Impact on Innovation
Responding to inquiries from the House Budget Committee, the Congressional Budget Office (CBO) has signaled its openness to examining new…
House Budget Committee Questions CBO’s Analysis of the IRA’s Impact on Drug Development
On November 20, 2023, the House Budget Committee addressed a letter to the Congressional Budget Office (CBO), expressing concerns and…
Aimed Alliance Comments on IRA Patient Listening Sessions
Recently, Aimed Alliance submitted a comment to the Centers for Medicaid and Medicare Services (CMS) on the Patient Listening Sessions…
New Report Highlights Value of Treatments to Patients
A recent report by the Alliance for Patient Access (AfPA) titled “At What Price? Medication Value, Patient Care & the…
GOA Finds Rebates Do Not Lower Consumer Costs
A recent report by the Government Accountability Office found that despite the substantial rebates private plans received for Medicare Part…
MDPC sends letter to MA Legislature on Use of QALYs
On September 19, 2023, the Movement Disorders Policy Coalition (MDPC) sent a letter to Chairwoman Friedman and Chairman Lawn of…